Meet or hear Laurie in one of the following:

InsureTech, Washington, DC, May 30, 2019

Silicon Valley Boomer Venture Summit, June 6, 2019

DC Longevity Summit, December, 2019

 

 

 

Related News Articles

02/18/2019

Connected devices that fuse health, technology and information.

02/15/2019

Juniper Research estimates about 8 billion voice assistants will be in use in 2023.

02/15/2019

Goal is to provide care, potentially diagnose disease.

02/15/2019

For integrators, the smart home technology opportunity for seniors is B2B.

02/13/2019

1000 care providers paying for medical rides so that patients do not miss appointments.

Market Overview for Technology for Aging in Place

You are here

BioSensics gets $4.3M from NIH for tools to monitor Cognitive Decline

BioSensics Announces a $4.3M Grant Award from the NIH to Develop Tools for Continuous, Remote Monitoring of Cognitive Decline in Dementia and Alzheimer’s Disease

September 26, 2018 10:00 AM Eastern Daylight Time

WATERTOWN, Mass.--(BUSINESS WIRE)--BioSensics LLC, a leader in developing wearable sensor technologies for clinical research and medical applications, has received a grant award from the National Institutes of Health (NIH) to develop technology for continuous, remote monitoring of cognitive decline. This technology will enable objective assessment of instrumental activities of daily living, life space, and also digital social interactions, which are biomarkers of many diseases and disorders from Alzheimer’s disease and dementia to depression. With the addition of this new technology, BioSensics seeks to expand the capabilities of its Sensor-Integrated Digital Platform for Clinical Trials to include tools for objective measurement of cognitive and mental health.

“Technology can play a key role in promoting healthy and independent aging. The ability to continuously monitor cognitive health plays a key role in managing care and support for the elderly population”

Dr. Joseph Gwin, Vice President of Research and Development at BioSensics, announced this NIH grant award yesterday during his presentation at DPharm: Disruptive Innovations to Advance Clinical Trials in Boston, MA, where Dr. Gwin discussed the critical role that wearable sensors can play in clinical trials. “BioSensics offers a wide range of solutions and services to measure movement and mobility related endpoints in clinical trials. We are thrilled to have the support of the NIH to further expand our offerings to measure endpoints that are directly relevant to a wide range of mental and cognitive disorders,” said Dr. Gwin.

The 3-year project will be conducted in collaboration with Baylor College of Medicine. The solution, which consists of a wearable movement sensor, GPS, and software for measuring digital social interactions, will have impacts in both clinical trials and clinical practice. “Technology can play a key role in promoting healthy and independent aging. The ability to continuously monitor cognitive health plays a key role in managing care and support for the elderly population,” said Dr. Bijan Najafi, professor in the Michael E. DeBakey Department of Surgery at Baylor College of Medicine, who is the Principal Investigator of the new grant award.

In May 2018, BioSensics announced the launch of its Sensor-Integrated Digital Platform for clinical trials. This platform was also developed in part with funding from the NIH and is currently being used in clinical trials for a variety of indications including neurodegenerative diseases, stroke, and cognitive disorders. “We have been very pleased with the favorable reception of our platform by the pharmaceutical industry and look forward to steady growth of our clinical trials division,” said Dr. Gwin.

Learn more at www.biosensics.com/solutions/clinical-trials

About BioSensics:
BioSensics is a globally recognized provider of wearable sensor technologies for clinical research and medical applications. BioSensics technologies include innovative solutions for aging-in-place, telehealth, chronic disease management, physical therapy, rehabilitation, fall risk assessment, and clinical research and trials.

Contacts

BioSensics
Kelly Urbany, 888-589-6213 ext. 700
kelly.urbany@biosensics.com

Wednesday, September 26, 2018

login account